Christina A Muzny1, Leandro A Mena2, Rebecca A Lillis3, Norine Schmidt4, David H Martin, Patricia Kissinger4. 1. From the Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL. 2. Division of Infectious Diseases and Department of Population Health Science, University of Mississippi Medical Center, Jackson, MS. 3. Section of Infectious Diseases, Louisiana State University Health Sciences Center. 4. Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
Abstract
BACKGROUND: In a randomized controlled trial of 2 g (single-dose) metronidazole (MTZ) versus 500 mg twice daily for 7 days (multidose) for Trichomonas vaginalis treatment, multidose was superior. We examined if the effect was similar by select clinical factors to determine if treatment recommendations could be targeted. METHODS: The primary outcome was T. vaginalis repeat infection at test-of-cure (TOC) 4 weeks after completion of therapy. Analyses were stratified by T. vaginalis history, baseline genital symptoms, and concurrent diagnosis of bacterial vaginosis (BV) per Nugent score at baseline. RESULTS: Women who returned for TOC (n = 540) were included. At baseline, 52.9% had a self-reported history of T. vaginalis; 79.3%, genital symptoms; 5.8%, a gonorrhea diagnosis; and 47.5%, BV. During follow-up, 97.4% took all MTZ as instructed and 34.5% had interval condomless sex with a baseline partner. At TOC, 14.8% tested positive for T. vaginalis. In stratified analysis, women randomized to single-dose MTZ had a higher rate of TOC T. vaginalis positivity than those randomized to multidose if they were symptomatic at baseline (21.4% vs. 10.8%, P = 0.003) or had a reported history of T. vaginalis (24.1% vs. 12.6%, P = 0.01). Test-of-cure T. vaginalis positivity was higher for women receiving a single dose (18.9%) versus multidose (10.8%), irrespective of baseline BV status (P > 0.06). In multivariable analysis, only a history of T. vaginalis and single-dose MTZ were independently associated with a positive TOC for T. vaginalis. CONCLUSIONS: Although multidose MTZ is recommended for all women with T. vaginalis, it is especially important for women with a T. vaginalis history and, given high posttreatment infection rates, a TOC should be performed.
BACKGROUND: In a randomized controlled trial of 2 g (single-dose) metronidazole (MTZ) versus 500 mg twice daily for 7 days (multidose) for Trichomonas vaginalis treatment, multidose was superior. We examined if the effect was similar by select clinical factors to determine if treatment recommendations could be targeted. METHODS: The primary outcome was T. vaginalis repeat infection at test-of-cure (TOC) 4 weeks after completion of therapy. Analyses were stratified by T. vaginalis history, baseline genital symptoms, and concurrent diagnosis of bacterial vaginosis (BV) per Nugent score at baseline. RESULTS: Women who returned for TOC (n = 540) were included. At baseline, 52.9% had a self-reported history of T. vaginalis; 79.3%, genital symptoms; 5.8%, a gonorrhea diagnosis; and 47.5%, BV. During follow-up, 97.4% took all MTZ as instructed and 34.5% had interval condomless sex with a baseline partner. At TOC, 14.8% tested positive for T. vaginalis. In stratified analysis, women randomized to single-dose MTZ had a higher rate of TOC T. vaginalis positivity than those randomized to multidose if they were symptomatic at baseline (21.4% vs. 10.8%, P = 0.003) or had a reported history of T. vaginalis (24.1% vs. 12.6%, P = 0.01). Test-of-cure T. vaginalis positivity was higher for women receiving a single dose (18.9%) versus multidose (10.8%), irrespective of baseline BV status (P > 0.06). In multivariable analysis, only a history of T. vaginalis and single-dose MTZ were independently associated with a positive TOC for T. vaginalis. CONCLUSIONS: Although multidose MTZ is recommended for all women with T. vaginalis, it is especially important for women with a T. vaginalis history and, given high posttreatment infection rates, a TOC should be performed.
Authors: Thomas A Peterman; Lin H Tian; Carol A Metcalf; C Kevin Malotte; Sindy M Paul; John M Douglas Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jennifer E Balkus; Barbra A Richardson; Lorna K Rabe; Taha E Taha; Nyaradzo Mgodi; Margaret Phiri Kasaro; Gita Ramjee; Irving F Hoffman; Salim S Abdool Karim Journal: Sex Transm Dis Date: 2014-02 Impact factor: 2.830
Authors: Kimberly A Workowski; Laura H Bachmann; Philip A Chan; Christine M Johnston; Christina A Muzny; Ina Park; Hilary Reno; Jonathan M Zenilman; Gail A Bolan Journal: MMWR Recomm Rep Date: 2021-07-23
Authors: Hanneke Borgdorff; Evgeni Tsivtsivadze; Rita Verhelst; Massimo Marzorati; Suzanne Jurriaans; Gilles F Ndayisaba; Frank H Schuren; Janneke H H M van de Wijgert Journal: ISME J Date: 2014-03-06 Impact factor: 10.302
Authors: Christina A Muzny; Jane R Schwebke; Paul Nyirjesy; Gregory Kaufman; Leandro A Mena; Gweneth B Lazenby; Olivia T Van Gerwen; Keonte J Graves; Janeen Arbuckle; Belvia A Carter; Connette P McMahon; Scott Eder; Jackie Shaw; Brajesh Pandey; Steven E Chavoustie Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079